Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
The world can avoid a recession but it won't think it can until it does, says David Roche
12:41am, Monday, 20'th Jun 2022
Everyone appears to be "rivaling each other to get the headlines and say the most awful things about the world," says veteran strategist David Roche.
My, Oh, My 11 Incredible High-Yield Dividend Aristocrat Bear Market Buys
12:00pm, Saturday, 18'th Jun 2022
This bear market is the 2nd worst start to the year in US stock market history. And cracks are beginning to form in credit markets that could potentially send stocks falling even lower in the coming m
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
10:50am, Friday, 17'th Jun 2022
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints
01:52pm, Thursday, 16'th Jun 2022
Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
08:36am, Thursday, 16'th Jun 2022
Roche Holdings AG (OTC: RHHBY) said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease. Crenezu
Heavy Buying Points to Upside for These 3 Stocks
06:01am, Wednesday, 08'th Jun 2022
With U.S. stocks showing signs of recovery, activity has picked up in recent weeks as traders seek to capitalize on a potential market bottom. Volume has been unusually high in the following three nam
Roche, Repare's licensing deal includes milestone payments worth up to $1.2 billion
08:00am, Thursday, 02'nd Jun 2022
Shares of Repare Therapeutics Inc. RPTX, -4.68% jumped 24.5% in premarket trading on Thursday, the day after the company said it signed a worldwide licensing and collaboration agreement with Roche Hol
Repare Therapeutics shares rise 18% after news of Roche deal
06:03pm, Wednesday, 01'st Jun 2022
Shares of Repare Therapeutics Inc. were trading higher in Wednesday's after-hours session, following news the company entered a worldwide license and collaboration agreement with Roche ROG, -1.13% to
Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension
03:49pm, Tuesday, 31'st May 2022
The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.
ASCO Presentations Could Move Shares of Daiichi, AstraZeneca, Gilead and Roche
03:09pm, Tuesday, 31'st May 2022
Investors will want to keep an eye on developments at this week's meeting of the American Society of Clinical Oncology in Chicago, where four members of big pharma will share study results of their mo
Why Roche Needs to Invest in At-Home Diagnostics
07:44am, Tuesday, 24'th May 2022
Declining demand for COVID-19 screening tests calls for a new focus.
Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
08:51am, Wednesday, 11'th May 2022
FRANKFURT (Reuters) -Development of a new cancer treatment pioneered by Roche was thrown into doubt on Wednesday when the immunotherapy drug failed to slow progression of lung cancer in a second trial
Roche's lung-cancer treatment fails in a clinical trial; its stock falls 7%
07:37am, Wednesday, 11'th May 2022
Roche Holding AG ROG, -6.27% said Wednesday that an experimental immunotherapy tested in combination with the cancer treatment Tecentriq failed to meet the primary co-endpoint of progression-free surv
Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs
12:47pm, Monday, 25'th Apr 2022
Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.
Roche said experimental breast-cancer therapy didn't meet main endpoint in a Phase 2 study
08:11am, Monday, 25'th Apr 2022
Roche Holding AG ROG, -2.41% said Monday that a Phase 2 clinical study evaluating giredestrant as a treatment for patients with advanced breast cancer did not meet its primary endpoint of progression-
